JAGX
Jaguar Health, Inc.
Next earnings Aug 12, 2026 · consensus $-1.52 EPS, $4.33M rev
$3.04
▲ +11.25%$3.04▼ -96.79%
over 1Y
L $2.25EODHDH $106.75
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+11.2%
1W+15.3%
1M-5.6%
3M-74.9%
YTD-91.4%
1Y-96.8%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 7 analysts
Buy
Conservative balance sheet (liabilities/equity -3.05x); but revenue declined -1.5% YoY.
Revenue (FY2025) $11.5M · FY2025
Jaguar Health, Inc. shows $11.5M in FY2025 revenue (-1.5% YoY), a -465.4% net margin.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $4.33M | $12.0M | $9.76M | $11.7M | $11.5M |
| Gross profit | — | — | — | — | — |
| Operating income | -$40.7M | -$34.4M | -$34.3M | -$30.8M | -$45.9M |
| Net income | — | -$47.5M | -$41.3M | -$38.5M | -$53.6M |
| Diluted EPS | -$88.22 | -$36.18 | -$2,678.17 | -$130.69 | -$22.97 |
| Net margin | — | -396.9% | -423.1% | -329.3% | -465.4% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$514M
EV / EBITDA—
EV / Sales44.6
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-10.5%
FCF yield-4.6%
Quality & risk
ROIC (est.)—
Free cash flow-$23.7M
Total debt$3.43M
Net cash-$2.46M
Altman Z-Score-13.52 distress
Piotroski F-Score3/8
Capital returns
Buyback yield0.0%
Dividend yield (est.)—
Shareholder yield0.0%
Shares Δ YoY+1101.6%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — late filing notice (2026-05-18). Worth a closer look.
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-222026-06-25open ↗8-K/APeriod ending 2026-06-222026-06-22open ↗8-KPeriod ending 2026-06-222026-06-22open ↗8-KPeriod ending 2026-06-172026-06-18open ↗8-KPeriod ending 2026-06-082026-06-11open ↗8-KPeriod ending 2026-06-082026-06-08open ↗8-KPeriod ending 2026-06-012026-06-02open ↗DEFA14AFiling2026-05-29open ↗8-KPeriod ending 2026-05-262026-05-27open ↗8-KPeriod ending 2026-05-212026-05-22open ↗8-KPeriod ending 2026-05-202026-05-20open ↗10-QPeriod ending 2026-03-312026-05-20open ↗
Frequently asked
- Is Jaguar Health, Inc. (JAGX) a buy?
- JAGX currently carries a Avoid rating with 3/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity -3.05x); but revenue declined -1.5% YoY.
- What is Jaguar Health, Inc.'s quality score?
- JAGX scores 20.941176470588236/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001585608, latest 10-Q filed 2026-05-20) · EODHD · as of 6/25/2026, 11:30:15 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.